Global Angioedema Treatment Market to Reach Worth Usd 1,658.0 Mn by 2022: Credence Research

According to the latest report published by Credence Research, Inc. “Angioedema Treatment Market Growth, Future Prospects and Competitive Analysis, 2016-2022,” the angioedema market was valued at USD 895.4 Mn in 2015, and is expected to reach USD 1,658.0 Mn by 2022, expanding at a CAGR of 9.2% from 2016 to 2022.

Browse the full report Angioedema Treatment Market Growth, Future Prospects and Competitive Analysis, 2016-2022report at http://www.credenceresearch.com/report/angioedema-treatment-market

Market Insights

Growth in healthcare investments, prevalence of angioedema and growing high-risk geriatric population are the major factors driving the global market growth for angioedema treatment. North America is the largest regional market at a market share of over 41% in 2015, and the dominance of this region is anticipated to continue through 2022. Rising incidence of angioedema and high awareness about treatment and the management of angioedema together drive the North America angioedema market. Asia Pacific is expected to be the fastest growing market in the global angioedema market due to rising prevalence rate in the countries like Japan, China and others. Moreover, the growing research and development in the drug discovery of angioedema would further drive the market during the forecast period.

Browse All Reports of This Category @ http://www.credenceresearch.com/industry/pharmaceuticals-market

The treatment types include Antihistamines, Corticosteroids, Autoimmune drugs, antifibrinolytic agents and blood protein controllers. Antihistamines and Corticosteroids accounted for approximately 45% - 50% of the total market share because these are the first line therapies preferred by the medical practitioners and majorly used as supportive therapies and most accessible source of treatment across the globe. Despite the high cost of new treatment options in comparison to older therapies such as attenuated androgens and antifibrinolytic agents, they are...